Veraxa Biotech Holding AG
Limited financial coverage for VRXA.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. [64, 65]
- CEO
- Christoph Antz
- IPO
- 2026
- Employees
- 8
- HQ
- Heidelberg, ZH, DE
Get TickerSpark's AI analysis on VRXA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- 52W High
- $27.36
- 52W Low
- $1.70
- 50D MA
- $7.24
- 200D MA
- $10.09
- Beta
- 0.25
- RSI (14)
- 37
- Avg Volume
- 418.16K
No earnings-call transcripts are available for VRXA yet.
- Free Float
- 8.9%
- Shares Outstanding
- 141.41M
- Float Shares
- 12.61M
Our VRXA coverage
Recent articles, reports, and earnings notes.
Want a deeper read on VRXA?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
globenewswire.com · Jul 27
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
globenewswire.com · Jul 27
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
globenewswire.com · Jul 24
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
globenewswire.com · Jul 23
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
globenewswire.com · Jul 20
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
globenewswire.com · Jul 13
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
globenewswire.com · Jul 13
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
globenewswire.com · Jul 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
Bullish or bearish?
Where do you stand on VRXA?